← All stocks

Kura Oncology, Inc.

KURA Net buying

CIK 0001422143 #2514 in the set updated 17 Sep 2026

Bought (12 mo)

$2.35M

out of their own pocket, the only kind of buying there is

Sold (12 mo)

$3.28M

$1.75M on a plan · $341.70K straight out of an exercise

Sold at will

$1.19M

23 of 36 sales

Net

−$930.94K

+$1.17M against sales at will

By person

9 insiders · 40 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

WILSON TROY EDWARD

President and CEO

$2.35M (2)

$327.42K (1)

+$2.02M

914,650

1.03%

$11.33M

+226.5%

Leoni Mollie

Chief Medical Officer

—

$1.19M (7) scheduled

−$1.19M

182,345

0.2050%

$2.26M

+288.2%

Bair Teresa Brophy

Chief Legal Officer

—

$690.81K (7) scheduled

−$690.81K

195,444

0.2197%

$2.42M

+168.5%

Powl Brian T.

Chief Commercial Officer

—

$397.89K (7)

−$397.89K

169,269

0.1903%

$2.10M

+979.7%

Burrows Francis

Chief Scientific Officer

—

$243.02K (2) scheduled

−$243.02K

32,424

0.0364%

$401.73K

+31.7%

FORD KATHLEEN

Chief Operating Officer

—

$174.59K (4) scheduled

−$174.59K

153,560

0.1726%

$1.90M

+22.5%

DOYLE THOMAS JAMES

SVP, Finance & Accounting

—

$151.76K (7)

−$151.76K

145,167

0.1632%

$1.80M

+175.7%

Hasnain Faheem

Director

—

$109.76K (1) scheduled

−$109.76K

23,983

0.0270%

$297.15K

0.0%

Malley Thomas

Director

—

10,000

0.0112%

$123.90K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Burrows Francis

18 Dec 2025

Chief Scientific Officer

Sold after exercise

23,726

$9.78

$231.93K

Hasnain Faheem

9 Dec 2025

Director

Sold after exercise

10,000

$10.98

$109.76K

Show all 40 transactions →

What was left out

Form 4 filings counted 46

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 11

Sales straight out of an exercise 2

Sales at will 23

Transactions with no price 0

Shares from compensation/vesting 1,155,686

History held since 3 Jan 2017